On the other hand, Talimogene laherparepvec (T-VEC), another oncolytic viral vaccine approved for melanoma therapy, selectively lyses the tumor cells to release tumor antigens [28,29] and also secretes granulocyte-macrophage colony-stimulating factor (GM-CSF), thereby recruiting dendritic cells (DC) to the tumor [30]. The gene discussed is CSF2; the disease is melanoma.